ICON (ICLR) Akcija Kursas
ICON Kursas
Per pastaruosius 19 metus ICON pajamos augo 16,5 % kasmet ir pasiekė 8,25 mlrd. USD. Pelnas akcijai augo 4,4 % per metus per pastaruosius 19 metus. ICON grynoji marža 2,8 % yra iš esmės stabili palyginti su 2,8 % prieš kelerius metus. ICON 12 mėn. konsensuso tikslinė kaina yra 175,00 USD, apie žemiau kursą 14,1 %. Iš 24 analitikų 15 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
ICON akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
ICON akcija ir akcijų analizė
Dažnai užduodami klausimai apie ICON akciją
The main competitors of ICON PLC in the market include other Contract Research Organizations (CROs) such as Covance Inc., QuintilesIMS Holdings Inc., and PAREXEL International Corporation. These companies provide similar services and solutions in the clinical research and development industry, offering competition to ICON PLC's global presence and expertise.
ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.
The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.
ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.
ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.
ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.
ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.
Analitikai šiuo metu nustato vidutinę ICON akcijos tikslinę kainą 170,64 USD (mediana: 175,00 USD), t. y. −16,3 % palyginti su paskutine kaina. Konsensusas pagrįstas 24 analitikų reitingais.
24 analitikai šiuo metu vertina ICON akciją: 15 rekomenduoja pirkti, 9 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad ICON gaus 8,16 mlrd. USD pajamų ir 11,47 USD pelno akcijai.
Pagal dabartinį kursą ICON akcija kainuoja 182,05 EUR (203,77 USD).
ICON akcija (ICLR) kotiruojama 4 biržose, įskaitant: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).
ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.
tikėtina pelnas ICON yra 8,16 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas ICON yra 878,58 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) ICON šiuo metu yra 17,76. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti ICON akcijos vertę.
Kainų ir pardavimų santykis (KUV) ICON šiuo metu yra 1,91. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra ICON akcijos įvertinimo metrika.
Eulerpool kokybės balas ICON yra 2/10.
ICON ISIN yra IE0005711209. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
ICON WKN yra 932242. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
ICON prekybos žymė yra ICLR. Ši biržos žymė naudojama ICON akcijoms prekiauti biržoje.
ICON akcija
Visos ICON pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė ICON akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai ICON. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: